Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma.

Interstitial pulmonary fibrosis is a common manifestation of systemic sclerosis (SSc) and is a pathologic feature shared by a variety of other diseases. In these other disease processes, the glycoprotein fibronectin (FN) has been shown to be released by the alveolar macrophage, and is thus implicated in the development of fibrosis. We therefore studied the release of FN by alveolar macrophages obtained by bronchoalveolar lavage of 17 patients with SSc and 14 controls. We found that SSc alveolar macrophages released significantly more FN than did those of controls. Furthermore, the level of FN correlated positively with the level of inflammation determined by cellular analysis of lavage fluid and negatively with carbon monoxide diffusing capacity. FN may therefore play a role in the development of lung fibrosis in SSc and may be a marker of alveolitis.

[1]  F. Baragar,et al.  The lungs in systemic sclerosis (scleroderma): a review and new information. , 1988, Seminars in arthritis and rheumatism.

[2]  B. Wallaert,et al.  Activated alveolar macrophages in subclinical pulmonary inflammation in collagen vascular diseases. , 1988, Thorax.

[3]  T. Pincus,et al.  Radiographic and joint count findings of the hand in rheumatoid arthritis. Related and unrelated findings. , 1988, Arthritis and rheumatism.

[4]  D. Furst,et al.  Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. , 1987, The American journal of medicine.

[5]  C. Nathan,et al.  Secretory products of macrophages. , 1987, The Journal of clinical investigation.

[6]  R. Silver,et al.  Interstitial lung disease in scleroderma. Immune complexes in sera and bronchoalveolar lavage fluid. , 1986, Arthritis and rheumatism.

[7]  T. Medsger,et al.  Role of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis. , 1986, The Journal of laboratory and clinical medicine.

[8]  Z. Cohn,et al.  The alveolar macrophage. , 1986, Journal of applied physiology.

[9]  M. Ramsden,et al.  Lung inflammation in scleroderma: clinical, radiographic, physiologic and cytopathological features. , 1985, The Journal of rheumatology.

[10]  V. Ferrans,et al.  Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. , 1985, The American review of respiratory disease.

[11]  M. Humphries,et al.  Recent advances in research on fibronectin and other cell attachment proteins , 1985, Journal of cellular biochemistry.

[12]  M. Hochberg,et al.  Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. , 1984, The American journal of medicine.

[13]  R. Silver,et al.  Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. , 1984, Arthritis and rheumatism.

[14]  M. Hochberg,et al.  Clinical and Demographic Predictors of Loss of Pulmonary Function in Systemic Sclerosis , 1984, Medicine.

[15]  A. Schutte,et al.  Local immune complexes and inflammatory response in patients with chronic interstitial pulmonary disorders associated with collagen vascular diseases. , 1984, Clinical and experimental immunology.

[16]  O. Braun-falco,et al.  Lung involvement in scleroderma. , 1984, Chest.

[17]  R. Crystal,et al.  Role of fibronectin as a growth factor for fibroblasts , 1983, The Journal of cell biology.

[18]  R. Rogers,et al.  Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. , 1983, Chest.

[19]  R. Crystal,et al.  Human alveolar macrophage growth factor for fibroblasts. Regulation and partial characterization. , 1982, The Journal of clinical investigation.

[20]  M. Hochberg,et al.  Serial pulmonary function in systemic sclerosis. , 1982, The American journal of medicine.

[21]  P. Haslam,et al.  Impaired antibody-dependent cell-mediated cytotoxicity in cryptogenic fibrosing alveolitis (synonym: idiopathic pulmonary fibrosis). , 1982, Clinical and experimental immunology.

[22]  D. Furst,et al.  Abnormalities of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis. , 1981, Arthritis and rheumatism.

[23]  R. Crystal,et al.  Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Wahl,et al.  Macrophage production of fibronectin, a chemoattractant for fibroblasts. , 1981, Journal of immunology.

[25]  G. Balian,et al.  Induction of fibroblast chemotaxis by fibronectin. Localization of the chemotactic region to a 140,000-molecular weight non-gelatin-binding fragment , 1981, The Journal of experimental medicine.

[26]  D. Hughes,et al.  Serial pulmonary function tests in progressive systemic sclerosis. , 1979, Thorax.

[27]  M. H. Williams,et al.  Serial changes in scleroderma and idiopathic interstitial lung disease. , 1973, Archives of internal medicine.

[28]  E. Leroy.  CONNECTIVE TISSUE SYNTHESIS BY SCLERODERMA SKIN FIBROBLASTS IN CELL CULTURE , 1972, The Journal of experimental medicine.

[29]  A. Masi,et al.  Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. , 1971, Annals of internal medicine.

[30]  J. Fries,et al.  Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. , 1969, The American journal of medicine.

[31]  A. Weaver,et al.  Clinical InvestigationsPulmonary Scleroderma , 1968 .

[32]  D. Hughes,et al.  Lung Function in Patients with Systemic Sclerosis , 1963, Thorax.